R21 Exploratory/Developmental Grant
Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21)
This Funding Opportunity Announcement (R21) outlines priority areas for high impact clinical and basic research for at-risk substance using populations, including those infected with or at risk for HIV. In particular, this FOA encourages research focused on prevention and treatment of Hepatitis C Virus (HCV) to reduce new infections and identify and treat existing infections more effectively. This FOA is informed by priority areas in the 2011 HHS Action Plan, Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care and Treatment of Viral Hepatitis.
|Notice(s) for this Opportunity|
|Letter of Intent Due Date|
|Application Due Date|Standard dates
apply, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.